When the Cardinals Waited to Plug In: Why Late Tech Adoption Can Be a Winning Playbook

There’s a slightly counterintuitive feeling that comes when you watch a team that’s known for tradition—like the St. Louis Cardinals—lean into modern performance tech. It’s comforting and a little thrilling at the same time: the same franchise that treasures history is now measuring spin efficiency in Jupiter and tracking ground reaction forces in the batting cages. But the bigger story here isn’t just “the Cardinals use tech.” It’s about timing: how waiting to adopt new technology can sometimes be an advantage rather than a handicap.

The hook: innovation without the bruises

Imagine buying a brand-new gadget on day one versus buying it after a year of updates, bug fixes, and user feedback. Early adopters get the flash and the bragging rights, but they also wrestle with early faults, awkward workflows, and expensive pivots. Late adopters—if they pick wisely—get the polished version plus a map of what works and what doesn’t.

That’s the thesis behind a recent piece on Viva El Birdos, which walks through the tech the Cardinals are using (and slowly integrating) and argues the club’s later, deliberate approach may spare them many missteps common to teams that plunged in too fast. (vivaelbirdos.com)

Why the Cardinals’ timing looks smart

• They avoid teething problems. Early versions of hardware and software often change dramatically. Wait long enough and vendors iterate toward reliability, better documentation, and sensible workflows.
• They learn from others. By the time a tool reaches them, there’s often a body of case studies—what injuries it predicted poorly, which metrics were noise, how coaches actually use the dashboards.
• They get more interoperable systems. Early sports tech tended to be stovepiped: one vendor’s files didn’t play nicely with another’s. Later entrants often adopt common standards or offer integrations with the ecosystem (TrackMan, Rapsodo, etc.). (trackman.com)
• Budget discipline. Waiting lets a club prioritize spending on proven solutions and the right people to interpret the data, instead of chasing every shiny thing.

The tech the Cardinals are (or likely are) using

Viva El Birdos’ roundup reads like a checklist of modern baseball performance tools—most of which are now common across MLB clubs, though the timing and depth of deployment vary: (vivaelbirdos.com)

• Force plates (e.g., Forcedecks) to measure drive and deceleration forces in pitchers.
• Arm-care and range-of-motion sensors for release-point strength checks and daily self-testing.
• TrackMan for full ball-trajectory and spin metrics—the workhorse of stadium and practice analytics. (trackman.com)
• Rapsodo systems and newer PRO devices for portable, detailed ball-flight and spin data useful in both hitting and pitching work. (rapsodo.com)
• Trajekt pitching simulators that emulate live pitcher release and pitch shapes for hitters.
• Kinatrax and other markerless motion-capture tools that let teams analyze in-game biomechanics without body markers.
• Edgertronic high-speed cameras for frame-by-frame spin and release detail.
• NordBord and groin/hip strength testing rigs to quantify rotational power and injury risk.
• Wearables and embedded sensors (sleeves, shoe plates, GPS/IMUs like Catapult) for workload and fatigue management.

Together, these tools create a matrix of data: mechanical forces, joint kinematics, ball flight, internal workload, and recovery indicators. The real art—and major expense—is turning that matrix into actionable, human-led decisions.

Late adoption: the tradeoffs and practical gains

• Reduced trial-and-error: The Cardinals (and teams that follow this path) can skip failed experiments other teams used as public beta tests.
• Better vendor maturity: Hardware durability, battery life, cloud reliability, and analytics UI often improve significantly after a product’s first 12–24 months on the market.
• Smarter hiring: Rather than hiring a stack of generalists, a team can recruit specialists who know the refined tools and workflows that actually move outcomes.
• Focused integration: Rather than attaching every sensor to every uniform, a later adopter can implement a streamlined stack that interoperates and produces clean signals for coaching and medical staff.
• But: late adoption risks missing early competitive edges and the institutional learning that comes from building expertise over time. The solution is selective adoption—waiting for evidence while experimenting in controlled ways.

How measured adoption looks in practice

• Start with high-signal tools. TrackMan and Rapsodo have become standard for a reason: they provide clear, reproducible metrics that feed scouting, player development, and in-game adjustments. (trackman.com)
• Pilot niche tech where risk is low. Try force plates and markerless capture with a small group (rehab pitchers, minor-league staff) before scaling.
• Build data ops and human interpreters first. Devices generate numbers; the value comes when physiotherapists, pitching coaches, and data scientists translate numbers into biomechanics and training plans.
• Use tech to augment, not replace, judgment. Advanced cameras and sensors illuminate details that were once invisible—use them to inform decisions rather than dictate them.

Lessons for other teams and organizations

• Timing is strategic. You can treat the adoption curve as a resource allocation problem: when do you spend on hardware vs. talent vs. integration?
• Expect consolidation. Vendors consolidate and best practices emerge; buying into a mature standard often means less technical debt.
• Invest in explainability. Coaches need interpretable metrics. If a metric can’t be explained in plain terms (what to change, how to change it, and why it matters), it’s probably not ready for daily use.
• Measure ROI beyond wins. Quantify effects on injury reduction, player availability, and rehab timelines—not just spin rate or exit velocity.

What this means for fans and those who follow the Cardinals

• You’ll see more subtle changes than instant results. Technology rarely instantaneously turns prospects into All-Stars, but it can steadily reduce injury rates, optimize workloads, and eke out small, repeatable performance gains.
• The narrative won’t be “we bought X and won.” It will be slower: better-managed pitchers, smarter rest schedules, individualized development plans—incremental advantages that compound.

A few practical cautions

• Beware metric inflation. More numbers often mean more noise. Teams must test whether a metric predicts outcomes (health, performance) or merely correlates superficially.
• Privacy and player buy-in matter. Wearable tracking and health monitoring require trust, clear consent, and good communication about how data is used.
• Don’t let tech short-circuit human relationships. The best results come when coaches use data as a conversation starter—not a final verdict.

My take

The Cardinals’ approach—methodical, observant, and willing to adopt proven tech rather than chase every novelty—feels like a franchise-calibrated strategy. It leverages one of the club’s true strengths: institutional patience. In a league where marginal gains matter and injuries can derail seasons, late-but-intelligent adoption can deliver a cleaner, sustainable path to competitive advantage.

If you squint, it’s the baseball version of “buy quality after the bugs are fixed.” You still need to spend—and you still must staff the right people—but when done thoughtfully, waiting can be an edge, not a delay.

Quick practical takeaways

• Waiting can be smart—if you use the pause to study outcomes, vendors, and integrations.
• Prioritize high-signal tools (ball flight + workload tracking) before adding niche hardware.
• Invest in interpreters (trainers, biomechanists, data analysts) as much as devices.
• Use pilots to scale safely and won’t overwhelm players or staff.

Sources

• The St. Louis Cardinals: Baseball meets Technology — Viva El Birdos (Jan 9, 2026).
  https://www.vivaelbirdos.com/st-louis-cardinals-news/66443/the-st-louis-cardinals-baseball-meets-technology. (vivaelbirdos.com)

• TrackMan Portable B1: Key Metrics for Pitching and Hitting — TrackMan.
  https://www.trackman.com/baseball/Portable-B1/what-we-track. (trackman.com)

• Rapsodo PRO 3.0 and PRO 2.0 product pages and announcements — Rapsodo.
  https://rapsodo.com/products/rapsodo-pro-3 and https://rapsodo.com/products/pro-2-dual-baseball-softball-flight-monitor. (rapsodo.com)

• Rapsodo PRO 3.0 product background (industry writeup) — ABCA / Inside Pitch Magazine.
  https://www.abca.org/magazine/magazine/2022-4-July_August/Last_Inning_Rapsodo_PRO3.aspx. (abca.org)

Final thought: technology won’t replace baseball’s human core, but the right timing—and the right people interpreting the right signals—can make the difference between expensive experiment and consistent improvement.

Johnson & Johnson’s deal with the U.S. government: what it means for drug prices, tariffs, and American manufacturing

A deal that’s equal parts policy, public relations, and industrial strategy landed on January 8, 2026: Johnson & Johnson announced a voluntary agreement with the U.S. government to lower medicine costs for millions of Americans while securing an exemption from potential tariffs — and pledging new domestic manufacturing investments. It’s one of several recent pacts between major drugmakers and the administration, and it touches on three hot-button issues at once: affordability, trade policy, and reshoring of pharmaceutical production. (jnj.com)

Why this caught headlines

• The company says millions of Americans will be able to buy J&J medicines at “significantly discounted rates” through a direct purchasing pathway described in the announcement. (jnj.com)
• In exchange, J&J’s pharmaceutical products receive an exemption from tariffs under the administration’s Section 232 trade scrutiny — a form of regulatory certainty that can materially affect margins and strategy. (jnj.com)
• The firm also confirmed further U.S. investment: two additional manufacturing facilities (cell therapy in Pennsylvania; drug product manufacturing in North Carolina) as part of its previously announced $55 billion U.S. investment plan. (jnj.com)

Those three elements—price concessions, tariff relief, and capital commitments—create a compact meant to satisfy both political and business imperatives. But beneath the headlines are subtler trade-offs and questions about scope, transparency, and longer-term impact.

Quick takeaways for readers scanning this

• J&J will offer discounted medicines to Americans via a direct-purchase program; exact drugs and discount levels were not disclosed in the press release. (jnj.com)
• The agreement provides a tariff exemption tied to continued U.S. investment in manufacturing, echoing similar arrangements other pharma firms have struck. (pharmamanufacturing.com)
• J&J is moving forward on domestic capacity: new sites in North Carolina and Pennsylvania add to its ongoing $55 billion commitment to U.S. manufacturing and R&D. (jnj.com)

Context: where this fits into the bigger picture

Drug pricing has been a political lightning rod for years. Policymakers are pushing for lower out-of-pocket costs and for the U.S. to stop shouldering a disproportionate share of global drug prices. At the same time, the administration’s tariff and trade posture has created uncertainty for multinational pharma companies that import materials or finished products. The recent flurry of voluntary agreements — in which companies promise price concessions or program participation in exchange for regulatory certainty and encouragement to invest domestically — is an attempt to square those circles. (reuters.com)

From industry perspective, the carrot of tariff relief plus a runway for U.S.-based manufacturing can be persuasive. From public interest and policy angles, voluntary deals leave open questions about which medicines are affected, how savings are passed to patients and taxpayers, and what accountability measures exist. Several recent announcements from peers show similar frameworks; secrecy around specific terms is a recurring criticism. (pharmamanufacturing.com)

What to watch next

• Specific drug list and discount details: The J&J release did not name which medicines would be included or the depth of discounts. Those details determine whether the move benefits a broad population or a narrower set of patients. (jnj.com)
• Timeline and duration of the tariff exemption: Other agreements have included multi-year grace periods; the length and conditionality matter for corporate planning and taxpayer exposure. (pharmamanufacturing.com)
• Job creation and plant timelines: J&J projects thousands of construction and manufacturing jobs from its investments; tracking actual hiring and capital deployment will show how much reshoring is real vs. aspirational. (jnj.com)
• Regulatory and legislative interplay: Ongoing Medicare negotiation rules, state-level reforms, and future trade actions could change incentives and the real-world effect of voluntary pacts. (apnews.com)

The investor dilemma

For investors, these deals can be double-edged:

• Positive: tariff certainty and clearer regulatory backdrop can reduce downside risk and encourage capital spending that strengthens future growth. (jnj.com)
• Negative: pricing concessions and participation in discount platforms could compress margins, especially if applied to high-revenue drugs or expand over time. Transparency around which products are included will be crucial to modeling impacts. (reuters.com)

My take

This agreement is smart politics and pragmatic business strategy wrapped together. It’s pragmatic because it buys the company regulatory breathing room and a path to expand domestic capacity—both defensible corporate goals. It’s political because offering discounted access addresses immediate public anger over drug prices, even if the long-term structural drivers of U.S. drug costs are not fully resolved by voluntary deals alone. What matters now is follow-through: clear lists of included medicines, measurable patient savings, and verifiable timelines for the manufacturing investments. Without those, good press risks becoming little more than a headline. (jnj.com)

Final thoughts

Deals like this will likely keep appearing as administrations try to lower healthcare costs without upending the pharmaceutical innovation engine. For patients, any program that lowers out-of-pocket costs is welcome — provided the discounts are meaningful and accessible. For policymakers and watchdogs, the job is to demand the transparency and metrics that turn press releases into policy outcomes: who benefits, by how much, and for how long.

Sources

• Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments — Johnson & Johnson. https://www.jnj.com/media-center/press-releases/johnson-johnson-reaches-agreement-with-u-s-government-to-improve-access-to-medicines-and-lower-costs-for-millions-of-americans-delivers-on-u-s-manufacturing-and-innovation-investments
• J&J strikes deal with US government to cut drug prices, gain tariff exemptions — Reuters (Jan 9, 2026). https://www.reuters.com/business/healthcare-pharmaceuticals/johnson-johnson-reaches-deal-with-us-government-lower-drug-prices-2026-01-09/
• J&J secures tariff exemption in drug pricing deal with Trump administration — Pharma Manufacturing. https://www.pharmamanufacturing.com/facilities/article/55342361/jj-secures-tariff-exemption-in-drug-pricing-deal-with-trump-administration
• Trump administration says lower prices for 15 Medicare drugs will save taxpayers billions — Associated Press. https://apnews.com/article/53602fe0b5b7800030c475c3a5f34c3c

Late-Game Grit: Michigan State’s Second-Half Surge Over Northwestern

There’s something about the Breslin Center that stretches late leads into victories and tests freshmen nerves — and on January 8, 2026, Michigan State reminded everyone why. Trailing by seven at halftime, the No. 12 Spartans flipped the script, outscoring Northwestern 48-31 in the second half to walk away with a 76-66 win. It was a night of momentum swings, timely threes, and the kind of physical rebounding that turned opportunity into points.

Game flow and what mattered

• Michigan State trailed 35-28 at the break but dominated after halftime, finishing with a 76-66 final.
• The Spartans outhustled the Wildcats on the glass, winning the rebound battle 42-25 and producing 16 second-chance points.
• Jaxon Kohler’s two big threes in the second half (one to take the lead) and Jeremy Fears Jr.’s 15 second-half points were the turning points.
• Northwestern’s Nick Martinelli poured in 28 points, but he got little support — the Wildcats had just one other player in double figures.

Why the second half swung to MSU

• Rebounding edge: Michigan State’s 42 rebounds (11 offensive) created extra possessions and pressure. When a team converts offensive boards into second-chance points, late deficits become manageable.
• Clutch shooting from unexpected spots: Kohler — normally a paint presence — stepped out and drilled two threes that erased Northwestern’s halftime cushion and swung momentum.
• Free-throw calm: After a sloppy first half at the line, MSU steadied itself in the second half (making 17 of 22) when the game tightened late.
• Bench and role-player contributions: Carson Cooper’s efficient scoring (6-of-6 from the field) and Coen Carr’s highlight plays helped keep the Spartans’ attack balanced.

Northwestern’s deja vu problems

• Overreliance on Martinelli: He was sensational with 28 points, but the Wildcats lacked complementary scoring. Depth and scoring balance continue to be weak links in early Big Ten play.
• Defensive lapses on the perimeter: Leaving Kohler open for multiple threes was costly. In the modern game, forwards who can mark the arc punish teams that don’t adjust.
• Second-half execution: Northwestern’s defense faded when it mattered most and the rebounding gap allowed Michigan State to control tempo.

Moments that mattered most

• Kohler’s first go-ahead 3 midway through the second half — a possession that flipped the lead and the crowd’s vibe.
• A late stretch where Fears converted a layup and Cooper hit clutch free throws to push MSU back ahead after Northwestern cut it to two with about two minutes left.
• MSU’s ability to limit turnovers in the second half relative to the first, and to convert on free throws when pressure rose.

Game stat snapshot (highlights)

• Final: Michigan State 76, Northwestern 66.
• Rebounds: MSU 42 — NU 25.
• Leading scorers: Nick Martinelli (NU) 28; Carson Cooper (MSU) 18; Jeremy Fears Jr. (MSU) 15 (all in 2nd half); Jaxon Kohler (MSU) 15.
• Record impact: MSU improved to 14-2 (4-1 Big Ten); Northwestern fell to 8-7 (0-4 Big Ten).

Three quick takeaways

• Momentum is a fragile thing in the Big Ten; MSU showed again that depth + rebounding can erase an early deficit.
• Northwestern needs another reliable scoring option — relying on a single high-volume guard is a tough blueprint across league play.
• Versatile bigs who can hit threes (like Kohler) change matchups and force defensive adjustments that many teams struggle to execute on the fly.

My take

This felt like a classic Tom Izzo game — physical, opportunistic, and with players stepping into roles when the moment demanded it. Michigan State didn’t overcomplicate things: they grabbed rebounds, attacked the paint when it opened, and trusted veteran instincts in the closing minutes. Northwestern showed fight and a future building block in Nick Martinelli, but the Wildcats’ early Big Ten record makes it clear they need better offensive balance and mental toughness late in games.

Looking ahead

• Michigan State: The Spartans will want to build off this second-half blueprint — keep crashing the glass and keep role players ready to make plays beyond the arc.
• Northwestern: The Wildcats must find consistent secondary scoring and tighten perimeter defense to survive the Big Ten gauntlet.

Sources

• Michigan State 76-66 Northwestern (Jan 8, 2026) Game Recap — ESPN. https://www.espn.com/mens-college-basketball/recap/_/gameId/401825428
• Cooper’s Career-High 18 Points Leads No. 12 Michigan State Past Northwestern — Michigan State Athletics. https://msuspartans.com/news/2026/1/8/mens-basketball-coopers-career-high-18-points-leads-no-12-michigan-state-past-northwestern-76-66-in-front-of-izzone-alumni
• No. 12 Michigan State pushes past Northwestern in second half — Reuters. https://www.reuters.com/sports/basketball/no-12-michigan-state-pushes-past-northwestern-second-half–flm-2026-01-09/